UCB Divests Chinese Production Plant and Older Medications for $680 Million

UCB has sold its production plant and a portfolio of older medications in China for $680 million.
The sale is part of UCB's strategic efforts to focus on newer, more innovative products.
This move follows recent regulatory and market developments, including FDA rejections and approvals in other regions.
UCB has been active in various partnerships and product launches, including deals for epilepsy medicine and the approval of its complement inhibitor for generalized myasthenia gravis.
The company has also been involved in industry trade group dynamics, including its exit from the Biotechnology Innovation Organization (BIO) following similar moves by other major pharmaceutical companies.